Retraction to: Cancer Gene Therapy https://doi.org/10.1038/s41417-018-0031-4, published online 21 June 2018
The Editor-in-Chief has retracted this article after concerns were raised about the data reported. In Fig. 2C, the panels for mimic-miR182 treatment of SKBR3/TR cells, mimic-NC treatment of BT474/TR cells, and mimic-miR182 treatment of BT474/TR cells each appear highly similar to images published in a previous paper [1] with no common authors. In Fig. 2D, the panels for inhibitor-NC treatment of SKBR3 cells and inhibitor-miR-182 treatment of BT474 cells also appear highly similar to images previously published in the same paper. The Editor-in-Chief no longer has confidence in the reliability of this article’s findings or conclusions.
The authors did not respond to correspondence from the publisher about this retraction.
Reference
Gao H, Teng C, Huang W, Peng J, Wang C. SOX2 promotes the epithelial to mesenchymal transition of esophageal squamous cells by modulating Slug expression through the activation of STAT3/HIF-α signaling. Int J Mol Sci. 2015;16:21643–57. https://doi.org/10.3390/ijms160921643
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yue, D., Qin, X. Retraction Note: miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells. Cancer Gene Ther 31, 1103 (2024). https://doi.org/10.1038/s41417-024-00787-3
Published:
Issue date:
DOI: https://doi.org/10.1038/s41417-024-00787-3
